Blood naltrexone levels over time following naltrexone implant
MetadataShow full item record
Aims: Oral naltrexone is used in the management of both heroin and alcohol dependence. However, poor compliance has limited its clinical utility. The study's objective was to determine the period of therapeutic coverage (= 2 ng/ml) provided by a 3.3 g naltrexone subcutaneous implant compared with existing data on 1.1 g and 2.2 g implants. Methods: We assessed free blood naltrexone levels following treatment with a 3.3 g naltrexone implant in heroin dependent patients (n = 50) in Perth, Western Australia. Results were compared with previously collated data for patients treated with either a 1.1 g (n = 10) or 2.2 g (n = 24) implant. Results: Following 3.3 g naltrexone implant treatment, free blood naltrexone levels remained above 2 ng/ml for 145 days (95% CI 125-167). In comparison, 1.1 g or 2.2 g implant treatment resulted in 95 days (95% CI 69-121) and 136 days (95% CI 114-158) coverage, respectively. Conclusions: The 3.3 g implant provides longer therapeutic coverage than the 1.1 g implant but not significantly longer than the 2.2 g implant. © 2007 Elsevier Inc. All rights reserved.
Showing items related by title, author, creator and subject.
Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humansHulse, G.; Low, V.; Stalenberg, V.; Morris, N.; Thompson, R.; Tait, Robert; Phan, C.; Ngo, H.; Arnold-Reed, D. (2008)Ultrasound was used to assess the in vivo biodegradability of a sustained release poly(DL)lactide naltrexone implant in 71 persons previously treated for heroin dependence. We assessed 139 implant sites ranging from 2 to ...
Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantationNgo, H.; Tait, Robert; Hulse, G. (2008)Context: Most research on heroin dependence treatments assesses short-term changes in patients' self-reported drug use. To our knowledge, long-term sustainability of changes in patients' drug use and associated hospital ...
Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexoneHulse, G.; Morris, N.; Arnold-Reed, D.; Tait, Robert (2009)CONTEXT: Oral naltrexone hydrochloride effectively antagonizes heroin, but its utility is limited by patient noncompliance. Sustained-release preparations may overcome this limitation.OBJECTIVE: To compare the safety and ...